Notícias Cellectis SA - CLLS | Ações NASDAQ | ADVFN Brasil

Índice Bovespa

US Dollar vs BRL

Cadastre-se gratuitamente para obter cotações em tempo real, gráficos interativos, fluxo de opções ao vivo e muito mais.

Cadastre-se

Início
Investir
Ações
EUA
NASDAQ
Cellectis SA (CLLS)
Cellectis SA (CLLS) Notícias

Cellectis SA (CLLS)

2,12

-0,02

( -0,93% )

Atualizado: 12:58:45

Atrasado por 15 minutos

Discussões em tempo real e ideias de negociação: Negocie com confiança com nossa poderosa plataforma.

Cellectis Presents Multiple Strategies to Enhance CAR T-cell Efficacy in Solid Tumors at the SITC Annual Meeting

Cellectis Provides Business Updates and Financial Results for Third Quarter 2024

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Cellectis to Report Third Quarter 2024 Financial Results on November 4, 2024

Cellectis to Present Data on TALE-Base Editors and Non-Viral Gene Therapy at the ESGCT 31st Annual Congress

Form 6-K/A - Report of foreign issuer [Rules 13a-16 and 15d-16]: [Amend]

Cellectis Presents Pre-Clinical Evidence of MUC1 CAR T-cells Reducing Triple-Negative Breast Cancer While Preserving Safety

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Cellectis Publishes a Molecular Therapy Article on a SMART DUAL CAR T-cell Approach for Treating Recalcitrant Solid Tumors

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Cellectis Appoints Dr. Adrian Kilcoyne as Chief Medical Officer

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Cellectis Provides Financial Results for the Second Quarter 2024

FDA Grants Orphan Drug Designation to Cellectis’ CLLS52 (alemtuzumab) For ALL Treatment

FDA Grants Orphan Drug and Rare Pediatric Disease Designation Status to Cellectis’ UCART22 product candidate for Acute Lymphoblastic Leukemia (ALL) Treatment

Fóruns

Nenhuma Discussão Encontrada

Criar Nova Discussão

Prudential Financial

BNP Paribas Issuance

Delayed Upgrade Clock

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições